西达本胺联合传统药物治疗复发/难治性皮肤T细胞淋巴瘤2例  

Chidamide Combined with Traditional Medicine in the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma:Two Cases Report

作　　者：王冠钰 王艺萌[1] 张春雷[1] WANG Guanyu;WANG Yimeng;ZHANG Chunlei(Department of Dermatology,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院皮肤科,北京100191

出　　处：《中国皮肤性病学杂志》2024年第9期1000-1006,共7页The Chinese Journal of Dermatovenereology

基　　金：国家自然科学基金面上项目(81972560);北京自然科学基金面上项目(7202231);北京大学医学部青年培育项目(BMU2020PYB023)。

摘　　要：目的观察西达本胺联合传统药物治疗复发/难治性皮肤T细胞淋巴瘤的效果。方法采用西达本胺治疗原有系统治疗失败、出现疾病复发或治疗抵抗的皮肤T细胞淋巴瘤,观察其疗效和不良反应。结果纳入的2例患者分别诊断为晚期蕈样肉芽肿(T3N1M0B0,ⅡB期)及原发性皮肤外周T细胞淋巴瘤,非特指型(T3bN0M0)。在采用西达本胺联合传统药物的治疗方案后,诊断为蕈样肉芽肿的患者临床获得完全缓解,并保持疾病稳定至少1年,不良反应为中性粒细胞降低及血小板降低;诊断为原发性皮肤外周T细胞淋巴瘤的患者获得部分缓解,未见明显不良反应。结论西达本胺对复发/难治性皮肤T细胞淋巴瘤患者具有良好疗效,不良反应以血液学不良反应为主。Objective To observe the effect of chidamide combined with traditional medicine in the treatment of relapsed/refractory cutaneous T-cell lymphoma(R/R CTCL).Methods Chidamide-based therapy was used to treat patients with cutaneous T-cell lymphoma who had failed systemic treatment regimens,experienced disease progression,or developed treatment resistance.The therapeutic effect and adverse reactions were observed.Results Two patients diagnosed with advanced mycosis fungoides(T3N1M0B0,stageⅡB)and primary cutaneous peripheral T-cell lymphoma,not otherwise specified(T3bN0M0)were included.After treatment with chidamide in combination with traditional medicine,the patient diagnosed with mycosis fungoides achieved complete clinical remission and maintained disease stability for at least 1 year,with adverse reactions of neutropenia and thrombocytopenia.The patient diagnosed with primary cutaneous peripheral T-cell lymphoma achieved partial remission with no apparent adverse reactions.Conclusion Chidamide has a good therapeutic effect on patients with relapsed/refractory cutaneous T-cell lymphoma,with hematologic adverse reactions being the main adverse effects.

关 键 词：皮肤T细胞淋巴瘤 复发/难治性 西达本胺 蕈样肉芽肿 原发性皮肤外周T细胞淋巴瘤 非特指型 

分 类 号：R739.5[医药卫生—肿瘤]